Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus
NCT01414920 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2011
- Completion date
- August 31, 2012
- Enrollment
- 368 (actual)
- Sites
- 80
Conditions
As the registry lists them; a condition with its own page is linked.